ArticleJournal of neurology2017
Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- Methods of estimating prevalence of multiple sclerosis in six European healthcare data sources: a contribution from the ConcePTION project.European journal of epidemiology · 2026Article
- Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Identifying multiple sclerosis in women of childbearing age in six European countries: a contribution from the ConcePTION project.European journal of epidemiology · 2025Article
- The epidemiology, pathology and pathogenesis of MS: Therapeutic implications.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Breast Cancer Screening in Women With Multiple Sclerosis: A Mixed-Methods Study.European journal of neurology · 2025Article
- Thyroid function and multiple sclerosis: a two-sample mendelian randomization study and mediation analysis.Scientific reports · 2025Article
- Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database.European journal of neurology · 2025Observational
- Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.Neurology · 2024Article
- Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Prevalence, demographic and spatial distribution of treated epilepsy in France in 2020: a study based on the French national health data system.Journal of neurology · 2024Article
- Performance of administrative databases for identifying individuals with multiple sclerosis.Scientific reports · 2023Article
- Pregnancy-related healthcare utilization among women with multiple sclerosis.Frontiers in neurology · 2023Article
- Article
- Altered Immune Phenotypes andFrontiers in immunology · 2021Article
- Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France.PharmacoEconomics - open · 2020Article
- Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases.Nutrients · 2020Review
- Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.Neurology. Clinical practice · 2020Article
- Neurofibromatosis I and multiple sclerosis.Orphanet journal of rare diseases · 2020Article
- The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database.Frontiers in neurology · 2020Article
- Validation of multiple sclerosis diagnoses in the Swedish National Patient Register.European journal of epidemiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the prevalence of multiple sclerosis (MS) in France are scarce. National and regional updated estimates are needed to better plan health policies. In this nationwide study, we provided estimates of the prevalence of MS in France in 2012 and mortality rate in 2013. MS cases were identified in the French national health insurance database (SNIIRAM-PMSI) using reimbursement data for disease-modifying treatment, long-term disease status for MS, disability pension for MS, and hospitalisation for MS (MS ICD-10 code: G35). We identified 99,123 MS cases, corresponding to an overall crude prevalence rate of 151.2 per 100,000 inhabitants [95% confidence interval (CI) 150.3-152.2]: 210.0 per 100,000 in women (95% CI 208.4-211.5) and 88.7 per 100,000 in men (95% CI 87.6-89.7). The overall prevalence rate was 155.6 per 100,000 inhabitants (95% CI 154.7-156.6) after standardization on the 2013-European population. We observed a prevalence gradient with a higher prevalence (190-200 per 100,000) in North-Eastern France and a lower prevalence in Southern and Western France (126-140). The crude mortality rate in 2013 was 13.7 per 1,000 MS cases (11.4 in women and 20.3 in men). The standardized mortality ratio was 2.56 (95% CI 2.41-2.72). Our results revise upwards the estimation of MS prevalence in France and confirm the excess mortality of MS patients compared to the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.